Detalhe da pesquisa
1.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474768
2.
Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
Anticancer Drugs
; 30(7): e0764, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30950836
3.
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
J Thorac Oncol
; 17(12): 1415-1427, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35961520
4.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
Lung Cancer
; 162: 9-15, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34649106
5.
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
J Immunother Cancer
; 9(5)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34016723
6.
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Eur J Cancer
; 150: 224-231, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934059
7.
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
J Immunother Cancer
; 9(4)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827906
8.
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Eur J Cancer
; 148: 24-35, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721704
9.
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Expert Opin Biol Ther
; 20(3): 319-326, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32011207
10.
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
Adv Ther
; 37(3): 1145-1155, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32002809
11.
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077515
12.
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Clin Lung Cancer
; 21(6): 498-508.e2, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32680806
13.
Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
Am J Clin Oncol
; 42(11): 845-850, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31644442
14.
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.
Immunotherapy
; 10(8): 643-655, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562816
15.
Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Cancer
; 98(2): 337-43, 2003 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12872354